Lexeo Therapeutics and Johnson & Johnson Partner to Advance Localized Cardiac AAV Gene Therapy

Jan 08 , 2026

NEW YORK —January 8, 2026— Lexeo Therapeutics, Inc. (Nasdaq: LXEO) announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of viral gene therapy, combining Lexeo’s expertise in cardiac genetic medicine with Johnson & Johnson’s cardiovascular therapeutics and Impella™ heart pump technology.

The collaboration aims to accelerate development of a preclinical cardiac gene therapy target by exploring novel, localized routes of adeno-associated virus (AAV) administration designed to concentrate gene delivery directly to the heart. By leveraging Impella heart pumps, which provide direct cardiac unloading and enhanced myocardial perfusion, the partners seek to improve transgene delivery efficiency while reducing systemic exposure.

The approach is intended to lower required AAV doses, enhance cardiac-specific transgene expression, and potentially improve the safety and efficacy profile of gene therapy for genetically mediated cardiovascular diseases. The collaboration reflects growing interest in pairing gene therapy platforms with advanced circulatory technologies to overcome delivery challenges in cardiac indications.

Source:

https://www.globenewswire.com/news-release/2026/01/08/3215190/0/en/Lexeo-Therapeutics-Announces-Research-Collaboration-to-Explore-Targeted-Cardiac-Delivery-of-AAV-Gene-Therapy.html

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.